Tina E. Hulse
15 IP cases indexed. Covers patent matters.
Cases Presided Over
15 cases indexed | Page 1 of 1
Tempus AI, Inc. v.Guardant Health Inc.
The PTAB instituted an inter partes review of Guardant Health’s cfDNA sequencing patent after Foundation Medicine (Petitioner) showed a reasonable likelihood of success on an obviousness ground over several prior‑art references.
Tempus AI, Inc. v.Guardant Health Inc.
The PTAB affirmed Guardant Health’s patent on cfDNA tagging methods, finding none of the 29 challenged claims unpatentable after rejecting Tempus AI’s obviousness arguments.
Neurocrine Biosciences, Inc. v.Spruce Biosciences, Inc.
The PTAB held that Neurocrine Biosciences' challenge succeeded; claims 1‑25 of Spruce Biosciences' ’908 patent were found unpatentable for lack of written description under 35 U.S.C. §112(a). The Board applied Ariad standards and rejected the genus claim.
Neurocrine Biosciences, Inc. v.Spruce Biosciences, Inc.
The PTAB held that Neurocrine Biosciences’ challenge to Spruce Biosciences’ ’201 patent succeeded; all 19 claims were found unpatentable for lack of written description under §112(a).
Jeisys Medical Inc. et al. v.Serendia, LLC
The PTAB instituted an IPR challenging claims 13 and 14 of Serendia's patent, finding a reasonable likelihood of anticipation by the prior art reference Mehta. The case moves to trial phase after rejecting arguments for discretionary denial based on competitor relationships.
Jeisys Medical Inc. et al. v.Serendia, LLC
The PTAB instituted the IPR challenge against Serendia's '536 patent, finding a reasonable likelihood of unpatentability. The Board determined that prior art (Mehta) discloses the claimed depth control feature despite arguments for fixed-length needles.
Geneoscopy, Inc. v.Exact Sciences Corporation
Geneoscopy, Inc. successfully petitioned the PTAB to institute an IPR against Exact Sciences Corporation's patent (11634781). The Board found a reasonable likelihood of prevailing on all grounds, specifically regarding obviousness under 35 U.S.C. § 103.
Ilooda Co., Ltd. et al. v.Serendia, LLC
The PTAB institution decision found a reasonable likelihood of unpatentability for several claims in the dermatological treatment patent, primarily based on anticipation by reference Mehta. The Board rejected arguments for discretionary denial and proceeded with the IPR.
Ilooda Co., Ltd. et al. v.Serendia, LLC
The Board granted a joint motion to terminate the IPR as to Jeisys Medical Inc. following a settlement with Serendia, while allowing EndyMed petitioners to continue the review.
Jeisys Medical Inc. et al. v.Serendia, LLC
The Board granted a joint motion to terminate the IPR only for Jeisys Medical Inc. after a settlement with Serendia, while EndyMed remains as a petitioner. The settlement agreement was ordered confidential.
Tempus AI, Inc. v.Guardant Health Inc.
The PTAB affirmed Guardant Health's U.S. Patent 11,149,306 covering cell‑free DNA tagging and counting, finding none of the 29 challenged claims unpatentable after Tempus AI's IPR challenge.
Tempus AI, Inc. v.Guardant Health Inc.
The PTAB held that most of Guardant Health’s ’822 patent claims are obvious over prior‑art sequencing methods, cancelling claims 1‑11, 13, and 17‑20, while claim 12 remains patentable.
Geneoscopy, Inc. v.Exact Sciences Corporation
The PTAB instituted an IPR in a colorectal cancer screening case, finding a reasonable likelihood that Geneoscopy's challenged claims are unpatentable. The Board accepted the petitioner's argument that combinations of various prior art references teach every limitation of the claims with a reason for combination.
Adobe Inc. v.Jaffe, Jonathan
Adobe Inc. successfully convinced the PTAB to institute an IPR against Jonathan E. Jaffe regarding image integrity patents (6757828). The Board found a reasonable likelihood of prevailing on obviousness over prior art, specifically Glass et al., leading to trial preparation.
Jeisys Medical Inc. et al. v.Serendia, LLC
The PTAB granted a settlement‑based termination for Jeisys Medical in three IPRs while allowing the proceedings to continue for EndyMed. The settlement agreement was ordered to be kept confidential.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.